Sales & Earnings In Brief
This article was originally published in The Tan Sheet
Executive Summary
NBTY realizes income leap post Leiner integration: First-quarter net income soars 461 percent to $75.6 million from $13.5 million - or $1.18 diluted earnings per share compared to 21 cents - as NBTY put the costs of integrating Leiner Health Products behind it. Additionally, former Leiner customers that looked elsewhere for private-label manufacturing before NBTY acquired the firm have largely returned, said CEO Scott Rudolph during a Jan. 28 earnings call. "Much of the business has come back absolutely and some of it is on the way back," Rudolph said. The Ronkonkoma, N.Y.-based supplement firm reported net sales of $751.2 million in the October-December period, a jump of 13.8 percent. NBTY's wholesale/U.S. nutrition business expanded 15.8 percent to $471.1 million, and Rudolph said the company is in the early stages of expanding some of its domestic brands overseas. The European retail operation grew 12.8 percent to $176 million in the quarter as NBTY continued integrating the U.K. Julian Graves stores (1"The Tan Sheet" Nov. 30, 2009)
You may also be interested in...
Sanofi Eyes Chattem As Key Building Block For Global OTC Growth
Sanofi-Aventis' $1.9 billion bid for OTC and personal care product firm Chattem offers the French firm a coveted toehold in the sizeable U.S. consumer health care market while also opening potential opportunities in emerging markets
NBTY Prefers Strategic Over "Easy" Acquisitions, Looks To China
NBTY looks to continue making strategic rather than "easy" acquisitions and includes China in its target markets, President Harvey Kamil says
Sales & Earnings In Brief
Johnson & Johnson continues to slump: Chief Financial Officer and VP of Finance Dominic Caruso says the economic recession continues to impact negatively U.S. consumer buying and distributor inventory levels in the consumer products segment. During the firm's third-quarter earnings call Oct. 13, Caruso said J&J's "core strategy" to overcome the slump is to differentiate its products and develop strong consumer brands. J&J's U.S. consumer business in the July-September period declined 4.4 percent to $1.69 billion, while revenues for the international consumer segment fell 1.4 percent to $2.3 billion. The OTC/Nutritionals division in the U.S. declined 5.9 percent to $732 million, while the international division increased 0.8 percent to $666 million. According to J&J's same-day earnings release, low inventory build of allergy medicines partially offset strong inventory cough-and-cold product builds in anticipation of the flu season, J&J said. Private-label competition also impacted growth, the firm said